Business Context and Reporting Period
Company: ARTIVION, INC.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended March 31, 2026
Business Overview: Artivion is a leader in manufacturing and distributing medical devices (aortic stent grafts, heart valves, surgical sealants) and preservation services for cardiac and vascular tissues. The company operates two reportable segments: Medical Devices and Preservation Services.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $116,337 | $98,978 |
| Gross Margin | $75,448 | $63,577 |
| Gross Margin % | 65% | 64% |
| Operating Income | $5,787 | $2,145 |
| Net Income (Loss) | $1,417 | $(505) |
| Diluted EPS | $0.03 | $(0.01) |
| Cash from Operating Activities | $1,154 | $(16,953) |
| Cash and Cash Equivalents (End of Period) | $55,764 | $37,693 |
| Total Debt (Principal) | $220,000 | $220,000 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 18% year-over-year (YoY), driven by growth in aortic stent grafts (+21%), On-X products (+20%), and preservation services (+23%). Constant currency revenue growth was 12%.
- Profitability Turnaround: The company returned to profitability with Net Income of $1.4 million compared to a Net Loss of $0.5 million in Q1 2025. Operating income more than doubled to $5.8 million.
- Expense Management: Interest expense decreased significantly to $5.4 million from $7.7 million, primarily due to the settlement of Convertible Senior Notes in mid-2025 and lower variable interest rates.
- Cash Flow Improvement: Operating cash flow swung from a use of $17.0 million in Q1 2025 to a generation of $1.2 million in Q1 2026, aided by improved profitability and lower costs related to the 2024 cybersecurity incident.
- Investing Activities: Capital expenditures increased to $8.0 million (from $3.6 million), alongside $1.5 million in payments related to the PerClot sale and $1.0 million for Endospan agreements.
Guidance, Outlook, and Material Events
- Endospan Acquisition: Following FDA approval of the NEXUS Aortic Arch System in April 2026, Artivion exercised its option to acquire Endospan Ltd. in May 2026. The company borrowed $150 million under a new delayed draw term loan facility to fund the $135 million upfront purchase price.
- Convertible Notes Settlement: The company settled its $100 million Convertible Senior Notes in May/July 2025 via exchange for common stock, eliminating future interest obligations on this debt instrument.
- Regulatory Milestones: The AMDS Hybrid Prosthesis received a Humanitarian Device Exemption (HDE) in December 2024, driving revenue growth in North America. Full Premarket Approval (PMA) is anticipated in 2026.
- Tax Legislation: The "One Big Beautiful Bill Act" (OBBBA) enacted in July 2025 impacted the effective tax rate, resulting in a 318% tax benefit for Q1 2026 due to excess stock-based compensation deductions.
- Risk Factors: Significant risks include supply chain dependencies (single-source suppliers for key components), geopolitical instability affecting operations in Israel (Endospan manufacturing), and potential regulatory changes regarding tissue preservation (FDA guidance on tuberculosis risk).
Investor Verification Checklist
- Endospan Integration: Verify the timeline and financial impact of the $135 million Endospan acquisition and the associated $150 million debt drawdown.
- Debt Covenants: Confirm continued compliance with the 5.75x net leverage ratio covenant under the amended Ares Credit Agreement following the new debt draw.
- Regulatory Approvals: Monitor the status of the AMDS PMA application expected in 2026 and the potential reclassification of CryoValve SG pulmonary heart valves by the FDA.
- Contingent Consideration: Review the $62.3 million liability for Ascyrus contingent consideration, which is sensitive to revenue estimates and milestone achievements.
- Cybersecurity Recovery: Assess ongoing costs and operational impacts related to the 2024 cybersecurity incident, including insurance recoveries and infrastructure upgrades.